Assembly Biosciences Key Executives
This section highlights Assembly Biosciences's key executives, including their titles and compensation details.
Find Contacts at Assembly Biosciences
(Showing 0 of )
Assembly Biosciences Earnings
This section highlights Assembly Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
$10.70
Stock Price
$80.29M
Market Cap
73
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Assembly Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $28.52M | $7.16M | $- | $6.25M | $79.11M |
| Cost of Revenue | $- | $48.90M | $498.00K | $466.00K | $101.34K |
| Gross Profit | $28.52M | $-41.74M | $-498.00K | $5.79M | $79.00M |
| Gross Profit Ratio | 100.00% | -582.67% | - | 92.55% | 99.87% |
| Research and Development Expenses | $55.93M | $48.90M | $69.98M | $68.52M | $106.82M |
| General and Administrative Expenses | $18.01M | $22.91M | $24.13M | $28.78M | $37.06M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.01M | $22.91M | $24.13M | $28.78M | $37.06M |
| Other Expenses | $- | $- | $- | $41.64M | $- |
| Operating Expenses | $73.94M | $71.81M | $94.11M | $97.30M | $143.88M |
| Cost and Expenses | $73.94M | $71.81M | $94.11M | $97.30M | $143.88M |
| Interest Income | $5.57M | $3.45M | $1.02M | $302.00K | $2.62M |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $450.00K | $498.00K | $466.00K | $691.00K |
| EBITDA | $-45.42M | $-64.20M | $-92.59M | $-91.93M | $-64.78M |
| EBITDA Ratio | -159.26% | -896.22% | - | -1469.97% | -81.89% |
| Operating Income | $-45.42M | $-64.65M | $-94.11M | $-132.69M | $-64.78M |
| Operating Income Ratio | -159.26% | -902.50% | - | -2121.65% | -81.89% |
| Total Other Income Expenses Net | $5.57M | $3.45M | $1.02M | $302.00K | $2.62M |
| Income Before Tax | $-39.85M | $-61.20M | $-93.09M | $-132.39M | $-62.15M |
| Income Before Tax Ratio | -139.72% | -854.32% | - | -2116.82% | -78.57% |
| Income Tax Expense | $330.00K | $33.00K | $-1.02M | $-2.53M | $-2.62M |
| Net Income | $-40.18M | $-61.23M | $-92.07M | $-129.85M | $-59.53M |
| Net Income Ratio | -140.87% | -854.78% | - | -2076.35% | -75.25% |
| EPS | $-6.69 | $-13.38 | $-22.82 | $-2.79 | $-1.50 |
| EPS Diluted | $-6.69 | $-13.38 | $-22.82 | $-2.77 | $-1.50 |
| Weighted Average Shares Outstanding | 6.00M | 4.58M | 4.03M | 46.54M | 39.68M |
| Weighted Average Shares Outstanding Diluted | 6.00M | 4.58M | 4.03M | 46.85M | 39.68M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.36M | $6.84M | $8.53M | $5.79M | $7.16M | $- | $- | $- | $- | $- | $- | $- | $- | $6.25M | $- | $- | $1.04M | $34.61M | $39.38M | $4.08M |
| Cost of Revenue | $- | $- | $32.00K | $32.00K | $84.00K | $116.00K | $126.00K | $124.00K | $124.00K | $134.00K | $120.00K | $120.00K | $120.00K | $18.47M | $120.00K | $107.00K | $28.02M | $26.94M | $23.33M | $23.05M |
| Gross Profit | $7.36M | $6.84M | $8.50M | $5.75M | $7.08M | $-116.00K | $-126.00K | $-124.00K | $-124.00K | $-134.00K | $-120.00K | $-120.00K | $-120.00K | $-12.22M | $-120.00K | $-107.00K | $-26.99M | $7.67M | $16.05M | $-18.96M |
| Gross Profit Ratio | 100.00% | 100.00% | 99.62% | 99.45% | 98.83% | - | - | - | - | - | - | - | - | -195.39% | - | - | -2602.31% | 22.16% | 40.76% | -464.71% |
| Research and Development Expenses | $14.28M | $13.52M | $16.26M | $11.88M | $11.01M | $10.82M | $12.52M | $14.55M | $16.85M | $18.13M | $17.79M | $17.20M | $14.75M | $18.47M | $16.75M | $18.55M | $33.51M | $26.94M | $23.33M | $23.05M |
| General and Administrative Expenses | $4.61M | $4.29M | $4.48M | $4.63M | $8.71M | $4.22M | $4.96M | $5.01M | $6.12M | $5.27M | $6.78M | $5.96M | $6.50M | $6.66M | $6.92M | $8.70M | $7.17M | $11.69M | $9.47M | $8.73M |
| Selling and Marketing Expenses | $- | $- | $-32.00K | $-32.00K | $-84.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.61M | $4.29M | $4.45M | $4.60M | $8.62M | $4.22M | $4.96M | $5.01M | $6.12M | $5.27M | $6.78M | $5.96M | $6.50M | $6.66M | $6.92M | $8.70M | $7.17M | $11.69M | $9.47M | $8.73M |
| Other Expenses | $- | $- | $-16.26M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $41.64M | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $18.89M | $17.80M | $20.70M | $16.48M | $19.63M | $15.05M | $17.49M | $19.56M | $22.98M | $23.40M | $24.57M | $23.16M | $21.25M | $25.13M | $23.67M | $27.26M | $40.68M | $38.63M | $32.80M | $31.77M |
| Cost and Expenses | $18.89M | $17.80M | $20.74M | $16.51M | $19.71M | $15.05M | $17.49M | $19.56M | $22.98M | $23.40M | $24.57M | $23.16M | $21.25M | $25.13M | $23.67M | $27.26M | $40.68M | $38.63M | $32.80M | $31.77M |
| Interest Income | $1.12M | $1.34M | $1.46M | $1.65M | $1.62M | $628.00K | $592.00K | $609.00K | $583.00K | $256.00K | $112.00K | $71.00K | $101.00K | $72.00K | $71.00K | $58.00K | $224.00K | $670.00K | $691.00K | $1.04M |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $256.00K | $112.00K | $71.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $32.00K | $33.00K | $32.00K | $32.00K | $84.00K | $116.00K | $126.00K | $124.00K | $124.00K | $134.00K | $120.00K | $120.00K | $120.00K | $119.00K | $120.00K | $107.00K | $314.00K | $140.00K | $122.00K | $115.00K |
| EBITDA | $-11.50M | $-10.92M | $-12.17M | $-10.70M | $-12.47M | $-14.93M | $-17.36M | $-19.43M | $-22.85M | $-23.40M | $-24.34M | $-23.04M | $-18.38M | $-18.76M | $-23.55M | $-27.15M | $-39.10M | $-3.88M | $6.70M | $-27.58M |
| EBITDA Ratio | -156.31% | -159.58% | -142.63% | -184.91% | -174.05% | - | - | - | - | - | - | - | - | -299.90% | - | - | -3770.88% | -11.21% | 17.02% | -675.79% |
| Operating Income | $-11.53M | $-10.96M | $-12.20M | $-10.73M | $-12.55M | $-15.05M | $-17.49M | $-19.56M | $-22.98M | $-23.40M | $-24.57M | $-23.16M | $-62.89M | $-18.88M | $-23.67M | $-27.26M | $-39.64M | $-4.02M | $6.58M | $-27.69M |
| Operating Income Ratio | -156.75% | -160.06% | -143.01% | -185.46% | -175.22% | - | - | - | - | - | - | - | - | -301.81% | - | - | -3822.76% | -11.61% | 16.71% | -678.61% |
| Total Other Income Expenses Net | $1.12M | $1.34M | $1.46M | $1.65M | $1.62M | $628.00K | $592.00K | $609.00K | $583.00K | $256.00K | $112.00K | $71.00K | $101.00K | $72.00K | $71.00K | $58.00K | $224.00K | $670.00K | $691.00K | $1.04M |
| Income Before Tax | $-10.41M | $-9.61M | $-10.75M | $-9.08M | $-10.93M | $-14.42M | $-16.90M | $-18.95M | $-22.39M | $-23.14M | $-24.46M | $-23.09M | $-62.79M | $-18.80M | $-23.59M | $-27.20M | $-39.42M | $-3.35M | $7.27M | $-26.66M |
| Income Before Tax Ratio | -141.51% | -140.44% | -125.93% | -156.91% | -152.58% | - | - | - | - | - | - | - | - | -300.66% | - | - | -3801.16% | -9.68% | 18.46% | -653.15% |
| Income Tax Expense | $-76.00K | $- | $406.00K | $-11.28K | $33.00K | $-116.00K | $3.92K | $-609.00K | $-766.00K | $-256.00K | $-112.00K | $-71.00K | $-2.53M | $- | $- | $- | $- | $- | $- | $-115.00K |
| Net Income | $-10.34M | $-9.61M | $-11.15M | $-9.08M | $-10.96M | $-14.42M | $-16.90M | $-18.34M | $-21.63M | $-22.89M | $-24.35M | $-23.02M | $-60.26M | $-18.80M | $-23.59M | $-27.20M | $-39.42M | $-3.35M | $7.27M | $-26.66M |
| Net Income Ratio | -140.48% | -140.44% | -130.69% | -156.91% | -153.04% | - | - | - | - | - | - | - | - | -300.66% | - | - | -3801.16% | -9.68% | 18.46% | -653.15% |
| EPS | $-1.72 | $-1.51 | $-1.98 | $-1.66 | $-2.00 | $-3.29 | $-3.88 | $-4.31 | $-5.32 | $-0.47 | $-0.50 | $-0.48 | $-1.34 | $-0.41 | $-0.55 | $-0.69 | $-0.99 | $-0.09 | $0.21 | $-0.76 |
| EPS Diluted | $-1.72 | $-1.51 | $-1.98 | $-1.66 | $-2.00 | $-3.29 | $-3.88 | $-4.31 | $-5.32 | $-0.47 | $-0.50 | $-0.48 | $-1.32 | $-0.41 | $-0.55 | $-0.69 | $-0.99 | $-0.09 | $0.19 | $-0.76 |
| Weighted Average Shares Outstanding | 6.00M | 6.35M | 5.64M | 5.48M | 5.48M | 4.38M | 4.36M | 4.25M | 4.07M | 48.45M | 48.29M | 48.12M | 44.95M | 45.57M | 42.88M | 39.68M | 39.68M | 35.51M | 35.31M | 35.08M |
| Weighted Average Shares Outstanding Diluted | 6.00M | 6.35M | 5.64M | 5.48M | 5.48M | 4.38M | 4.36M | 4.25M | 4.07M | 48.45M | 48.29M | 48.12M | 45.57M | 45.57M | 42.88M | 39.68M | 39.68M | 35.51M | 37.29M | 35.08M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $38.34M | $19.84M | $52.42M | $45.63M | $59.44M |
| Short Term Investments | $73.73M | $110.41M | $39.19M | $101.00M | $156.97M |
| Cash and Short Term Investments | $112.08M | $130.25M | $91.61M | $146.63M | $216.41M |
| Net Receivables | $- | $43.00K | $944.00K | $336.00K | $1.23M |
| Inventory | $- | $-3.20M | $1 | $1 | $0 |
| Other Current Assets | $3.42M | $6.69M | $4.41M | $14.48M | $13.70M |
| Total Current Assets | $115.50M | $133.79M | $96.97M | $154.20M | $224.49M |
| Property Plant Equipment Net | $3.35M | $2.72M | $3.94M | $7.18M | $10.73M |
| Goodwill | $- | $- | $- | $- | $12.64M |
| Intangible Assets | $- | $- | $- | $- | $29.00M |
| Goodwill and Intangible Assets | $- | $- | $- | $-1.54M | $41.64M |
| Long Term Investments | $- | $- | $- | $27.97M | $-7.26M |
| Tax Assets | $- | $- | $811.00K | $1.54M | $7.26M |
| Other Non-Current Assets | $312.00K | $312.00K | $78.00K | $1.70M | $6.39M |
| Total Non-Current Assets | $3.67M | $3.04M | $4.83M | $36.86M | $58.76M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $119.17M | $136.82M | $101.79M | $191.06M | $283.25M |
| Account Payables | $585.00K | $461.00K | $2.49M | $2.66M | $4.60M |
| Short Term Debt | $461.00K | $1.22M | $6.73M | $6.30M | $6.81M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $37.62M | $30.91M | $2.73M | $2.73M | $8.99M |
| Other Current Liabilities | $9.13M | $6.63M | $7.08M | $7.11M | $13.03M |
| Total Current Liabilities | $47.80M | $39.23M | $16.30M | $16.07M | $24.43M |
| Long Term Debt | $2.63M | $1.12M | $101.00K | $3.33M | $6.72M |
| Deferred Revenue Non-Current | $- | $55.38M | $2.73M | $2.73M | $8.99M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-2.73M | $-2.73M | $2.53M |
| Other Non-Current Liabilities | $35.38M | $- | $- | $- | $- |
| Total Non-Current Liabilities | $38.01M | $56.50M | $2.83M | $6.06M | $18.24M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $85.81M | $95.73M | $19.13M | $22.13M | $42.68M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $5.00K | $49.00K | $48.00K | $34.00K |
| Retained Earnings | $-825.92M | $-785.75M | $-724.52M | $-631.43M | $-501.57M |
| Accumulated Other Comprehensive Income Loss | $-211.00K | $-81.00K | $-803.00K | $-419.00K | $-270.00K |
| Other Total Stockholders Equity | $859.49M | $826.92M | $807.94M | $800.73M | $742.39M |
| Total Stockholders Equity | $33.36M | $41.10M | $82.66M | $168.93M | $240.58M |
| Total Equity | $33.36M | $41.10M | $82.66M | $168.93M | $240.58M |
| Total Liabilities and Stockholders Equity | $119.17M | $136.82M | $101.79M | $191.06M | $283.25M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $119.17M | $136.82M | $101.79M | $191.06M | $283.25M |
| Total Investments | $73.73M | $110.41M | $39.19M | $128.97M | $156.97M |
| Total Debt | $3.09M | $2.34M | $3.46M | $6.48M | $10.13M |
| Net Debt | $-35.26M | $-17.50M | $-48.95M | $-39.15M | $-49.31M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $38.34M | $28.45M | $19.21M | $18.75M | $19.84M | $26.66M | $21.62M | $43.48M | $52.42M | $54.67M | $43.06M | $51.17M | $45.63M | $70.76M | $59.52M | $78.25M | $59.44M | $58.31M | $96.71M | $42.33M |
| Short Term Investments | $73.73M | $66.50M | $90.01M | $94.23M | $110.41M | $19.55M | $38.21M | $29.53M | $39.19M | $53.98M | $73.63M | $71.83M | $101.00M | $110.14M | $139.56M | $136.63M | $156.97M | $179.63M | $130.00M | $206.80M |
| Cash and Short Term Investments | $112.08M | $94.95M | $109.22M | $112.98M | $130.25M | $46.21M | $59.83M | $73.02M | $91.61M | $108.65M | $116.69M | $123.00M | $146.63M | $180.90M | $199.08M | $214.88M | $216.41M | $237.94M | $226.71M | $249.13M |
| Net Receivables | $- | $- | $- | $43.00K | $43.00K | $- | $342.00K | $717.00K | $944.00K | $1.25M | $523.00K | $524.00K | $336.00K | $769.00K | $297.00K | $203.00K | $1.23M | $3.59M | $3.31M | $3.06M |
| Inventory | $- | $- | $- | $- | $1 | $-100.00K | $- | $- | $1 | $1 | $0 | $- | $1 | $1 | $1 | $1 | $1 | $1 | $1 | $- |
| Other Current Assets | $3.42M | $3.26M | $3.71M | $4.15M | $6.69M | $3.46M | $3.91M | $6.01M | $4.41M | $10.36M | $14.16M | $7.25M | $14.48M | $13.10M | $12.37M | $13.09M | $13.70M | $9.71M | $10.12M | $9.14M |
| Total Current Assets | $115.50M | $98.21M | $112.93M | $117.17M | $133.79M | $49.67M | $64.08M | $79.74M | $96.97M | $115.08M | $124.29M | $130.78M | $154.20M | $188.22M | $205.56M | $221.63M | $224.49M | $246.39M | $235.09M | $256.75M |
| Property Plant Equipment Net | $3.35M | $1.74M | $2.08M | $2.40M | $2.72M | $1.41M | $2.16M | $3.04M | $3.94M | $4.83M | $5.61M | $6.32M | $7.18M | $8.01M | $8.85M | $9.60M | $10.73M | $12.30M | $12.84M | $13.26M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $12.64M | $12.64M | $12.64M | $12.64M | $12.64M | $12.64M | $12.64M |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.00M | $29.00M | $29.00M | $29.00M | $29.00M | $29.00M | $29.00M |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.54M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M | $41.64M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $11.91M | $23.46M | $27.97M | $9.18M | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $646.00K | $- | $- | $- | $811.00K | $- | $- | $- | $1.54M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $312.00K | $312.00K | $312.00K | $312.00K | $312.00K | $552.00K | $332.00K | $334.00K | $78.00K | $1.61M | $1.64M | $2.17M | $1.70M | $1.92M | $6.09M | $6.03M | $6.39M | $5.98M | $5.23M | $1.66M |
| Total Non-Current Assets | $3.67M | $2.05M | $2.39M | $2.71M | $3.68M | $1.96M | $2.50M | $3.37M | $4.83M | $6.44M | $19.15M | $31.95M | $36.86M | $60.75M | $56.58M | $57.27M | $58.76M | $59.92M | $59.71M | $56.56M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $119.17M | $100.26M | $115.32M | $119.88M | $137.47M | $51.63M | $66.58M | $83.12M | $101.79M | $121.52M | $143.45M | $162.73M | $191.06M | $248.97M | $262.14M | $278.90M | $283.25M | $306.31M | $294.80M | $313.31M |
| Account Payables | $585.00K | $1.33M | $801.00K | $727.00K | $461.00K | $758.00K | $904.00K | $1.22M | $2.49M | $1.94M | $2.45M | $1.41M | $2.66M | $2.63M | $2.87M | $3.56M | $4.60M | $1.61M | $3.64M | $2.10M |
| Short Term Debt | $461.00K | $1.33M | $2.59M | $2.29M | $1.22M | $1.74M | $3.40M | $5.09M | $3.36M | $6.74M | $6.62M | $6.41M | $3.15M | $6.20M | $6.10M | $5.87M | $3.40M | $6.68M | $6.50M | $6.53M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $37.62M | $32.62M | $33.06M | $32.77M | $30.91M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $8.99M | $8.99M | $8.99M | $8.99M | $- | $6.71M |
| Other Current Liabilities | $9.13M | $6.35M | $4.82M | $2.96M | $6.63M | $4.64M | $4.52M | $3.65M | $10.44M | $6.78M | $5.88M | $2.89M | $10.26M | $6.10M | $4.95M | $5.07M | $16.43M | $8.52M | $7.13M | $5.80M |
| Total Current Liabilities | $47.80M | $41.63M | $41.27M | $38.75M | $39.23M | $7.13M | $8.83M | $9.97M | $16.30M | $15.46M | $14.96M | $10.71M | $16.07M | $14.93M | $13.91M | $14.50M | $24.43M | $16.80M | $17.27M | $21.15M |
| Long Term Debt | $2.63M | $113.00K | $451.00K | $791.00K | $1.12M | $50.00K | $64.00K | $80.00K | $101.00K | $918.00K | $1.77M | $2.50M | $3.33M | $4.14M | $4.91M | $5.64M | $6.72M | $7.43M | $7.88M | $8.54M |
| Deferred Revenue Non-Current | $35.38M | $32.51M | $38.92M | $47.74M | $55.38M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $2.73M | $8.99M | $8.99M | $8.99M | $8.99M | $-7.88M | $29.33M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-38.92M | $-47.74M | $646.00K | $-2.73M | $-2.73M | $-2.73M | $811.00K | $-2.73M | $-2.73M | $-2.73M | $1.54M | $2.53M | $2.53M | $2.53M | $2.53M | $2.53M | $2.53M | $2.53M |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $38.01M | $32.62M | $39.37M | $48.53M | $57.15M | $2.78M | $2.80M | $2.81M | $2.83M | $3.65M | $4.51M | $5.23M | $6.06M | $9.40M | $16.43M | $17.16M | $18.24M | $18.95M | $10.41M | $40.40M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $85.81M | $74.26M | $80.64M | $87.28M | $96.37M | $9.91M | $11.63M | $12.78M | $19.13M | $19.11M | $19.47M | $15.94M | $22.13M | $24.33M | $30.34M | $31.66M | $42.68M | $35.76M | $27.69M | $61.54M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $6.00K | $6.00K | $5.00K | $5.00K | $53.00K | $52.00K | $52.00K | $49.00K | $48.00K | $48.00K | $48.00K | $48.00K | $47.00K | $44.00K | $40.00K | $34.00K | $33.00K | $33.00K | $32.00K |
| Retained Earnings | $-825.92M | $-815.59M | $-805.98M | $-794.83M | $-785.75M | $-774.79M | $-760.37M | $-743.47M | $-724.52M | $-702.12M | $-678.98M | $-654.52M | $-631.43M | $-571.17M | $-552.37M | $-528.77M | $-501.57M | $-462.15M | $-458.81M | $-466.08M |
| Accumulated Other Comprehensive Income Loss | $-211.00K | $-156.00K | $-293.00K | $-239.00K | $-81.00K | $-275.00K | $-325.00K | $-513.00K | $-803.00K | $-999.00K | $-998.00K | $-908.00K | $-419.00K | $-288.00K | $-273.00K | $-271.00K | $-270.00K | $-158.00K | $104.00K | $-86.00K |
| Other Total Stockholders Equity | $859.49M | $841.74M | $840.95M | $827.66M | $826.92M | $816.72M | $815.59M | $814.26M | $807.94M | $805.48M | $803.91M | $802.17M | $800.73M | $796.06M | $784.39M | $776.25M | $742.39M | $732.83M | $725.78M | $717.90M |
| Total Stockholders Equity | $33.36M | $26.00M | $34.68M | $32.60M | $41.10M | $41.71M | $54.95M | $70.33M | $82.66M | $102.40M | $123.98M | $146.79M | $168.93M | $224.65M | $231.79M | $247.24M | $240.58M | $270.55M | $267.12M | $251.77M |
| Total Equity | $33.36M | $26.00M | $34.68M | $32.60M | $41.10M | $41.71M | $54.95M | $70.33M | $82.66M | $102.40M | $123.98M | $146.79M | $168.93M | $224.65M | $231.79M | $247.24M | $240.58M | $270.55M | $267.12M | $251.77M |
| Total Liabilities and Stockholders Equity | $119.17M | $100.26M | $115.32M | $119.88M | $137.47M | $51.63M | $66.58M | $83.12M | $101.79M | $121.52M | $143.45M | $162.73M | $191.06M | $248.97M | $262.14M | $278.90M | $283.25M | $306.31M | $294.80M | $313.31M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $119.17M | $100.26M | $115.32M | $119.88M | $137.47M | $51.63M | $66.58M | $83.12M | $101.79M | $121.52M | $143.45M | $162.73M | $191.06M | $248.97M | $262.14M | $278.90M | $283.25M | $306.31M | $294.80M | $313.31M |
| Total Investments | $73.73M | $66.50M | $90.01M | $94.23M | $110.41M | $19.55M | $38.21M | $29.53M | $39.19M | $53.98M | $85.53M | $95.28M | $101.00M | $119.32M | $139.56M | $136.63M | $156.97M | $179.63M | $130.00M | $206.80M |
| Total Debt | $3.09M | $1.44M | $1.75M | $1.94M | $2.34M | $919.00K | $1.77M | $2.63M | $3.46M | $4.29M | $5.08M | $5.70M | $6.48M | $7.24M | $7.96M | $8.58M | $10.13M | $10.77M | $11.13M | $11.80M |
| Net Debt | $-35.26M | $-27.01M | $-17.46M | $-16.81M | $-17.50M | $-25.74M | $-19.86M | $-40.86M | $-48.95M | $-50.38M | $-37.98M | $-45.47M | $-39.15M | $-63.52M | $-51.55M | $-69.67M | $-49.31M | $-47.54M | $-85.58M | $-30.52M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-40.18M | $-61.23M | $-93.09M | $-129.85M | $-62.15M |
| Depreciation and Amortization | $129.00K | $450.00K | $498.00K | $466.00K | $691.00K |
| Deferred Income Tax | $- | $-7.15M | $- | $-2.53M | $-4.00K |
| Stock Based Compensation | $3.12M | $5.12M | $6.59M | $5.24M | $21.85M |
| Change in Working Capital | $-11.95M | $76.34M | $-2.12M | $-11.40M | $-30.31M |
| Accounts Receivables | $43.00K | $901.00K | $-608.00K | $894.00K | $2.14M |
| Inventory | $- | $- | $- | $-4.10M | $-7.26M |
| Accounts Payables | $124.00K | $-2.03M | $-166.00K | $-1.94M | $2.87M |
| Other Working Capital | $-12.12M | $77.47M | $-1.35M | $-6.25M | $-28.06M |
| Other Non Cash Items | $-2.24M | $9.21M | $3.66M | $44.69M | $6.96M |
| Net Cash Provided by Operating Activities | $-51.12M | $22.74M | $-84.46M | $-93.40M | $-62.96M |
| Investments in Property Plant and Equipment | $-28.00K | $-255.00K | $-102.00K | $-3.10M | $-2.22M |
| Acquisitions Net | $- | $- | $1.50M | $1.50M | $1.75M |
| Purchases of Investments | $-94.16M | $-133.92M | $-27.58M | $-160.45M | $-193.19M |
| Sales Maturities of Investments | $130.70M | $65.02M | $116.83M | $187.70M | $263.48M |
| Other Investing Activities | $3.66M | $24.00K | $90.74M | $857.00K | $-1.75M |
| Net Cash Used for Investing Activities | $40.17M | $-69.14M | $90.64M | $26.52M | $68.07M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $29.29M | $13.69M | $325.00K | $52.81M | $5.45M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $155.00K | $129.00K | $289.00K | $258.00K | $2.15M |
| Net Cash Used Provided by Financing Activities | $29.45M | $13.82M | $614.00K | $53.06M | $7.60M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $18.50M | $-32.58M | $6.79M | $-13.82M | $12.71M |
| Cash at End of Period | $38.34M | $19.84M | $52.42M | $45.63M | $59.44M |
| Cash at Beginning of Period | $19.84M | $52.42M | $45.63M | $59.44M | $46.73M |
| Operating Cash Flow | $-51.12M | $22.74M | $-84.46M | $-93.40M | $-62.96M |
| Capital Expenditure | $-28.00K | $-255.00K | $-102.00K | $-3.10M | $-2.22M |
| Free Cash Flow | $-51.15M | $22.49M | $-84.56M | $-96.49M | $-65.18M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-10.34M | $-9.61M | $-11.15M | $-9.08M | $-10.96M | $-14.42M | $-16.90M | $-18.95M | $-22.39M | $-23.14M | $-24.46M | $-23.09M | $-60.26M | $-18.80M | $-23.59M | $-27.20M | $-39.42M | $-3.35M | $7.27M | $-26.66M |
| Depreciation and Amortization | $32.00K | $33.00K | $32.00K | $32.00K | $84.00K | $116.00K | $126.00K | $124.00K | $124.00K | $134.00K | $120.00K | $120.00K | $120.00K | $119.00K | $120.00K | $107.00K | $314.00K | $140.00K | $122.00K | $115.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-1.47M | $-313.00K | $-169.00K | $- | $- | $- | $- | $- | $-2.53M | $149.00K | $171.00K | $1.70M | $76.00K | $21.00K | $34.00K | $-135.00K |
| Stock Based Compensation | $751.00K | $797.00K | $833.00K | $739.00K | $959.00K | $1.14M | $1.19M | $1.83M | $2.01M | $1.56M | $1.58M | $1.44M | $1.95M | $1.59M | $1.99M | $-286.00K | $3.75M | $6.05M | $7.13M | $4.92M |
| Change in Working Capital | $9.38M | $15.36M | $-6.21M | $-9.15M | $83.50M | $-880.00K | $4.39M | $-7.24M | $222.00K | $753.00K | $3.92M | $-7.02M | $1.64M | $-2.84M | $-1.39M | $-8.80M | $6.51M | $6.63M | $-38.83M | $-4.62M |
| Accounts Receivables | $- | $- | $43.00K | $- | $-43.00K | $342.00K | $375.00K | $227.00K | $302.00K | $-723.00K | $1.00K | $-188.00K | $433.00K | $-472.00K | $-94.00K | $1.03M | $2.36M | $-275.00K | $-260.00K | $319.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-464.00K | $-175.42M | $-192.25M | $-215.93M | $-198.90M | $-1.45M | $-2.67M | $-4.30M |
| Accounts Payables | $-750.00K | $534.00K | $74.00K | $266.00K | $-297.00K | $-146.00K | $-320.00K | $-1.27M | $551.00K | $-512.00K | $1.05M | $-1.25M | $31.00K | $-238.00K | $-696.00K | $-1.04M | $2.99M | $-636.00K | $143.00K | $373.00K |
| Other Working Capital | $10.13M | $14.83M | $-6.33M | $-9.42M | $83.84M | $-1.08M | $4.34M | $1.04M | $-631.00K | $1.99M | $2.87M | $-5.58M | $1.64M | $173.29M | $191.65M | $207.14M | $200.06M | $8.99M | $-36.04M | $-1.01M |
| Other Non Cash Items | $-240.00K | $-21.82M | $174.00K | $-368.00K | $1.54M | $514.00K | $-2.27M | $803.00K | $782.00K | $880.00K | $956.00K | $1.04M | $39.73M | $903.00K | $902.00K | $1.14M | $3.50M | $1.16M | $1.16M | $1.15M |
| Net Cash Provided by Operating Activities | $-407.00K | $-15.24M | $-17.10M | $-18.36M | $73.65M | $-13.85M | $-13.63M | $-23.43M | $-19.25M | $-19.82M | $-17.89M | $-27.50M | $-19.36M | $-18.88M | $-21.81M | $-33.34M | $-25.27M | $10.65M | $-23.12M | $-25.22M |
| Investments in Property Plant and Equipment | $- | $- | $-14.00K | $-14.00K | $-71.00K | $-136.00K | $-48.00K | $- | $-102.00K | $-102.00K | $- | $- | $-18.00K | $- | $- | $-3.08M | $-1.75M | $-470 | $-405.00K | $-65.00K |
| Acquisitions Net | $- | $- | $- | $- | $24.00K | $-19.02K | $48.00K | $- | $- | $-31.53K | $- | $- | $586.00K | $- | $- | $857.00K | $1.75M | $- | $- | $-135.00K |
| Purchases of Investments | $-40.90M | $-17.78M | $-31.18M | $-3.71M | $-108.31M | $-2.65M | $-22.96M | $-52.00K | $-8.76M | $-2.97M | $-11.90M | $-3.95M | $-52.97M | $-22.68M | $-35.59M | $-49.21M | $-40.17M | $-108.78M | $2.00K | $-44.24M |
| Sales Maturities of Investments | $34.20M | $39.20M | $36.30M | $21.00M | $18.70M | $21.67M | $14.64M | $10.00M | $23.82M | $34.50M | $21.50M | $37.00M | $43.00M | $42.75M | $32.50M | $69.45M | $62.63M | $58.90M | $76.95M | $65.00M |
| Other Investing Activities | $- | $3.06M | $5.12M | $1.26M | $-89.58M | $19.02K | $-48.00K | $52.00K | $1.60M | $31.53K | $9.60M | $33.05M | $914.00K | $20.07M | $-3.09M | $857.00K | $-1.75M | $470 | $76.95M | $135.00K |
| Net Cash Used for Investing Activities | $-6.70M | $24.49M | $5.11M | $17.27M | $-89.65M | $18.88M | $-8.37M | $10.00M | $16.56M | $31.43M | $9.60M | $33.05M | $-8.48M | $20.07M | $-3.09M | $18.02M | $20.71M | $-49.89M | $76.55M | $20.69M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $16.90M | $-59.00K | $12.39M | $- | $9.14M | $- | $54.00K | $4.49M | $325.00K | $- | $177.00K | $- | $2.60M | $10.05M | $6.01M | $34.14M | $5.45M | $467 | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $96.00K | $-12.39M | $59.00K | $- | $49.00K | $- | $80.00K | $- | $112.00K | $- | $177.00K | $- | $114.00K | $- | $144.00K | $- | $5.69M | $843.00K | $950.00K | $119.00K |
| Net Cash Used Provided by Financing Activities | $17.00M | $- | $12.45M | $- | $9.19M | $- | $134.00K | $4.49M | $437.00K | $- | $177.00K | $- | $2.71M | $10.05M | $6.16M | $34.14M | $5.69M | $843.00K | $950.00K | $119.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $2.70M | $- | $23.05M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $9.89M | $9.24M | $459.00K | $-1.09M | $-4.12M | $5.03M | $-21.86M | $-8.94M | $-2.25M | $11.61M | $-8.11M | $5.55M | $-25.13M | $11.24M | $-18.74M | $18.81M | $1.13M | $-38.40M | $54.38M | $-4.41M |
| Cash at End of Period | $38.34M | $28.45M | $19.21M | $18.75M | $19.84M | $26.66M | $21.62M | $43.48M | $52.42M | $54.67M | $43.06M | $51.17M | $45.63M | $70.76M | $59.52M | $78.25M | $59.44M | $58.31M | $96.71M | $42.33M |
| Cash at Beginning of Period | $28.45M | $19.21M | $18.75M | $19.84M | $23.96M | $21.62M | $43.48M | $52.42M | $54.67M | $43.06M | $51.17M | $45.63M | $70.76M | $59.52M | $78.25M | $59.44M | $58.31M | $96.71M | $42.33M | $46.73M |
| Operating Cash Flow | $-407.00K | $-15.24M | $-17.10M | $-18.36M | $73.65M | $-13.85M | $-13.63M | $-23.43M | $-19.25M | $-19.82M | $-17.89M | $-27.50M | $-19.36M | $-18.88M | $-21.81M | $-33.34M | $-25.27M | $10.65M | $-23.12M | $-25.22M |
| Capital Expenditure | $- | $- | $-14.00K | $-14.00K | $-71.00K | $-136.00K | $-48.00K | $- | $-102.00K | $-102.00K | $- | $- | $-18.00K | $- | $- | $-3.08M | $-1.75M | $-470 | $-405.00K | $-65.00K |
| Free Cash Flow | $-407.00K | $-15.24M | $-17.12M | $-18.38M | $73.58M | $-13.98M | $-13.68M | $-23.43M | $-19.36M | $-19.92M | $-17.89M | $-27.50M | $-19.38M | $-18.88M | $-21.81M | $-36.42M | $-27.02M | $10.65M | $-23.52M | $-25.28M |
Assembly Biosciences Dividends
Explore Assembly Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Assembly Biosciences News
Read the latest news about Assembly Biosciences, including recent articles, headlines, and updates.
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose –
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D --
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2024.
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.
Assembly Biosciences Provides Anticipated Development Milestones for 2024
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
5 Penny Stocks With Big Black Friday Stock Market News
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news, rumors, and breakthroughs – allowing traders to potentially lock in short-term gains.
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023.
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies have entered into a 12-year partnership agreement.
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company's interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
-- Two oral presentations and one poster will feature new data from the Company's hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis B virus (HBV) and hepatitis D virus (HDV) pipeline programs at the 2023 International HBV Meeting taking place in Kobe, Japan, September 19-23, 2023.
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced data from development candidate ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor targeting high-recurrence genital herpes, featured in one oral and one poster presentation at the 47th Annual International Herpesvirus Workshop in Missoula, Montana, taking place July 15-19, 2023.
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board
BOSTON--(BUSINESS WIRE)--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver. “Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic.” Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founded and brought public two biotech companies, Assembly Biosciences (NASDAQ:ASMB) and Pardes Biosciences (NASDAQ:PRDS), building both from concept through clinical development. He has helped raise over $600M for his companies to advance novel therapies for Hepatitis B (ASMB) and SARS-CoV-2 (PRDS) infections.. Dr Lopatin was also a visiting partner at Y combinator, where he focused on early stage biotech investments. Dr. Lopatin completed his training in Internal Medicine at the University of Washington, and New York University and his fellowship training in Infectious Diseases at the NIH - National Institute of Allergy and Infectious Disease. Olivia Merkel, Ph.D. Dr. Merkel has been a Professor of Drug Delivery at LMU Munich since 2015 and Chair since 2022. She is a Registered Pharmacist, received a MS (2006) and a PhD (2009) in Pharmaceutical Technology as well as numerous awards, including an ERC Starting Grant, ERC Proof-of-Concept Grant, the APV Research Award and the Carl-Wilhelm-Scheele-Award. Merkel is the author of over 100 articles and book chapters. She served as NIH reviewer from 2014-2015, SNF reviewer from 2018-2022, is an Editorial Board member for JCR, EJPB, Molecular Pharmaceutics and other journals, was the President of the German Controlled Release Society in 2020 and the Chair of the CRS Focus Group on Transdermal and Mucosal Delivery from 2020-2022. Her research focuses mainly on RNA formulation and pulmonary delivery for the treatment of a variety of lung diseases. Neville Sanjana, Ph.D. Dr. Sanjana, is a Core Faculty Member at the New York Genome Center and an Associate Professor in the Departments of Biology and of Neuroscience and Physiology at New York University. As a bioengineer, Dr. Sanjana has developed high-throughput genome engineering tools to understand the impact of genetic changes on cancer evolution, viral pathogenesis, drug resistance and the nervous system. Dr. Sanjana is a recipient of the Presidential Early Career Award for Engineers and Scientists, AAAS Wachtel Prize for Cancer Research, the NIH’s New Innovator Award, the Cancer Research Institute Technology Impact Award, the DARPA Young Faculty Award, the Kimmel Scholar Award, the MRA Young Investigator Award, and also is the Leichtung Family Investigator of the Brain and Behavior Foundation. Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University. About Carver Biosciences, Inc. Carver is a Boston, MA-based gene therapy company developing CRISPR-based therapies for RNA viruses that infect humans. Carver’s approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence. The company’s underlying technology was developed by co-founder Dr. Cameron Myhrvold. For additional information, please visit www.carver.bio.
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ASMB.